Pre-order Enquiry
Request Free Sample
Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Research Report 2020
SKU ID : QYR-16533276 | Publishing Date : 12-Oct-2020 | No. of pages : 91
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Research Report 2020
1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Overview1.1 Product Overview and Scope of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
1.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type
1.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 1g/20ml
1.2.3 1.25g/25ml
1.2.4 2.5g/50ml
1.2.5 5g/100ml
1.2.6 10g/200ml
1.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application
1.3.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Estimates and Forecasts
1.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2015-2026
1.4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2015-2026
1.4.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region: 2020 Versus 2026
1.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry
1.6 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Trends
2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Competition by Manufacturers
2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Manufacturers (2015-2020)
2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2015-2020)
2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Sites, Area Served, Product Type
2.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Competitive Situation and Trends
2.5.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players (Opinion Leaders)
3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario by Region
3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
3.3.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.3.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
3.4.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.4.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Region
3.5.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region
3.5.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
3.6.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.6.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
3.7.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.7.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historic Market Analysis by Type
4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2015-2020)
4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2015-2020)
4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Market Share by Type (2015-2020)
4.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historic Market Analysis by Application
5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2015-2020)
5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2015-2020)
5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2015-2020)
6 Company Profiles and Key Figures in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Business
6.1 Boya-Bio
6.1.1 Corporation Information
6.1.2 Boya-Bio Description, Business Overview and Total Revenue
6.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Boya-Bio Products Offered
6.1.5 Boya-Bio Recent Development
6.2 Beijing Tiantan Biological Products
6.2.1 Beijing Tiantan Biological Products Corporation Information
6.2.2 Beijing Tiantan Biological Products Description, Business Overview and Total Revenue
6.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Beijing Tiantan Biological Products Products Offered
6.2.5 Beijing Tiantan Biological Products Recent Development
6.3 Hualan Bio
6.3.1 Hualan Bio Corporation Information
6.3.2 Hualan Bio Description, Business Overview and Total Revenue
6.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Hualan Bio Products Offered
6.3.5 Hualan Bio Recent Development
6.4 Guangdong Shuagnlin Bio-pharmacy
6.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
6.4.2 Guangdong Shuagnlin Bio-pharmacy Description, Business Overview and Total Revenue
6.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Guangdong Shuagnlin Bio-pharmacy Products Offered
6.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Development
6.5 Weiguang Biological
6.5.1 Weiguang Biological Corporation Information
6.5.2 Weiguang Biological Description, Business Overview and Total Revenue
6.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Weiguang Biological Products Offered
6.5.5 Weiguang Biological Recent Development
6.6 Sinopharm
6.6.1 Sinopharm Corporation Information
6.6.2 Sinopharm Description, Business Overview and Total Revenue
6.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Sinopharm Products Offered
6.6.5 Sinopharm Recent Development
6.7 Shanghai RAAS
6.6.1 Shanghai RAAS Corporation Information
6.6.2 Shanghai RAAS Description, Business Overview and Total Revenue
6.6.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Shanghai RAAS Products Offered
6.7.5 Shanghai RAAS Recent Development
6.8 CTBB
6.8.1 CTBB Corporation Information
6.8.2 CTBB Description, Business Overview and Total Revenue
6.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.8.4 CTBB Products Offered
6.8.5 CTBB Recent Development
6.9 Nanyue Biopharming
6.9.1 Nanyue Biopharming Corporation Information
6.9.2 Nanyue Biopharming Description, Business Overview and Total Revenue
6.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Nanyue Biopharming Products Offered
6.9.5 Nanyue Biopharming Recent Development
7 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Cost Analysis
7.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
7.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
8.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2021-2026)
10.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2021-2026)
10.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2021-2026)
10.4 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Estimates and Projections (2021-2026)
10.5 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Estimates and Projections (2021-2026)
10.6 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Estimates and Projections (2021-2026)
10.7 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Estimates and Projections (2021-2026)
10.8 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Figures, Tables and Charts Available in Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Research Report 2020
List of TablesTable 1. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Comparison by Application: 2020 VS 2026
Table 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type (K Units) (US$ Million) (2020 VS 2026)
Table 4. Global Key Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Covered in This Study
Table 5. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Manufacturers (2015-2020)
Table 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers (2015-2020)
Table 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Average Price (US$/Unit) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Sites and Area Served
Table 11. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Types
Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) as of 2019)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players
Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Region (2015-2020)
Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2015-2020)
Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) by Region (2015-2020)
Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2015-2020)
Table 20. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2015-2020) (K Units)
Table 21. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2015-2020)
Table 22. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2015-2020)
Table 24. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2015-2020) (K Units)
Table 25. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2015-2020)
Table 26. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2015-2020) (K Units)
Table 29. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2015-2020)
Table 32. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2015-2020) (K Units)
Table 33. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2015-2020)
Table 34. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2015-2020) (K Units)
Table 37. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2015-2020)
Table 40. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Type (2015-2020)
Table 41. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2015-2020)
Table 42. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) by Type (2015-2020)
Table 43. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2015-2020)
Table 44. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (US$/Unit) by Type (2015-2020)
Table 45. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Application (2015-2020)
Table 46. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2015-2020)
Table 47. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate by Application (2015-2020)
Table 48. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 49. Boya-Bio Description and Business Overview
Table 50. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 51. Boya-Bio Main Product
Table 52. Boya-Bio Recent Development
Table 53. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 54. Beijing Tiantan Biological Products Corporation Information
Table 55. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 56. Beijing Tiantan Biological Products Main Product
Table 57. Beijing Tiantan Biological Products Recent Development
Table 58. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 59. Hualan Bio Corporation Information
Table 60. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 61. Hualan Bio Main Product
Table 62. Hualan Bio Recent Development
Table 63. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 64. Guangdong Shuagnlin Bio-pharmacy Corporation Information
Table 65. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 66. Guangdong Shuagnlin Bio-pharmacy Main Product
Table 67. Guangdong Shuagnlin Bio-pharmacy Recent Development
Table 68. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 69. Weiguang Biological Corporation Information
Table 70. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 71. Weiguang Biological Main Product
Table 72. Weiguang Biological Recent Development
Table 73. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 74. Sinopharm Corporation Information
Table 75. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 76. Sinopharm Main Product
Table 77. Sinopharm Recent Development
Table 78. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 79. Shanghai RAAS Corporation Information
Table 80. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 81. Shanghai RAAS Main Product
Table 82. Shanghai RAAS Recent Development
Table 83. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 84. CTBB Corporation Information
Table 85. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 86. CTBB Main Product
Table 87. CTBB Recent Development
Table 88. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Corporation Information
Table 89. Nanyue Biopharming Corporation Information
Table 90. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2015-2020)
Table 91. Nanyue Biopharming Main Product
Table 92. Nanyue Biopharming Recent Development
Table 93. Sales Base and Market Concentration Rate of Raw Material
Table 94. Key Suppliers of Raw Materials
Table 95. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
Table 96. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers List
Table 97. Market Key Trends
Table 98. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 99. Key Challenges
Table 100. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Forecast by Type (2021-2026)
Table 101. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Type (2021-2026)
Table 102. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) Forecast by Type (2021-2026)
Table 103. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 104. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Forecast by Application (2021-2026)
Table 105. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) Forecast by Application (2021-2026)
Table 106. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Forecast by Region (2021-2026)
Table 107. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Region (2021-2026)
Table 108. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 109. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Region (2021-2026)
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Figure 2. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type: 2020 VS 2026
Figure 3. 1g/20ml Product Picture
Figure 4. 1.25g/25ml Product Picture
Figure 5. 2.5g/50ml Product Picture
Figure 6. 5g/100ml Product Picture
Figure 7. 10g/200ml Product Picture
Figure 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Consumption Market Share by Application: 2020 VS 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size 2015-2026 (US$ Million)
Figure 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Capacity (K Units) (2015-2026)
Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers in 2020
Figure 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers in 2019
Figure 17. The Global 5 and 10 Largest Players: Market Share by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2019
Figure 18. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2015-2020)
Figure 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region in 2019
Figure 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2015-2020)
Figure 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region in 2019
Figure 23. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2019
Figure 24. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2019
Figure 25. U.S. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 26. U.S. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 28. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 29. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2019
Figure 30. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2019
Figure 31. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 32. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 34. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 38. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 40. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region in 2019
Figure 42. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region in 2019
Figure 43. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 44. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 46. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 48. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 50. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 52. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Taiwan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 54. Taiwan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Indonesia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 56. Indonesia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Thailand Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 58. Thailand Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Malaysia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 60. Malaysia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Philippines Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 62. Philippines Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Vietnam Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 64. Vietnam Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2019
Figure 66. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2019
Figure 67. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 68. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 70. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 72. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country in 2019
Figure 74. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country in 2019
Figure 75. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 76. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 78. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate (2015-2020) (K Units)
Figure 80. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Sales Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2015-2020)
Figure 82. Sales Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type in 2019
Figure 83. Revenue Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2015-2020)
Figure 84. Revenue Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type in 2019
Figure 85. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth by Type (2015-2020) (K Units)
Figure 86. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2015-2020)
Figure 87. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application in 2019
Figure 88. Global Revenue Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2015-2020)
Figure 89. Global Revenue Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application in 2020
Figure 90. Boya-Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Beijing Tiantan Biological Products Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Hualan Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. Guangdong Shuagnlin Bio-pharmacy Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Weiguang Biological Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Sinopharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Shanghai RAAS Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. CTBB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Nanyue Biopharming Total Revenue (US$ Million): 2019 Compared with 2018
Figure 99. Price Trend of Key Raw Materials
Figure 100. Manufacturing Cost Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Figure 101. Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Figure 102. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industrial Chain Analysis
Figure 103. Channels of Distribution
Figure 104. Distributors Profiles
Figure 105. Porter's Five Forces Analysis
Figure 106. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 107. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 108. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 109. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 110. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 111. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 112. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 113. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 114. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) and Growth Rate Forecast (2021-2026)
Figure 115. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 116. Bottom-up and Top-down Approaches for This Report
Figure 117. Data Triangulation
Figure 118. Key Executives Interviewed
Keyplayers in Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Research Report 2020
Boya-BioBeijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
